According to the package insert1, RotaTeq vaccine will prevent about 74 percent of rotavirus cases, about 98 percent of severe cases, and about 96 percent of hospitalizations due to rotavirus.
No efficacy or safety information is available on the use of RotaTeq in immunocompromised infants as this was not evaluated in clinical trials. Safety and efficacy information is also unavailable for use of the vaccine in infants with a history of gastrointestinal disease, including those with chronic diarrhea, acute gastrointestinal illness, history of congenital abdominal disorders, abdominal surgery, or failure to thrive.
RotaTeq may not prevent diarrhea or vomiting caused by viruses other than the rotavirus strains covered within the vaccine.
